Search - tctmd.com

Displaying 281 - 300 of 404

Sort: Relevancy | Date

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

AHA/ACC Aim to Enhance Care of High BP With New Measures

News Daily News

AHA/ACC Aim to Enhance Care of High BP With New Measures

November 14, 2019

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

October 21, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

Direct Sodium Removal With an Ambulatory Peritoneal Dialysis System: Sequana

Presentation TCT 2019

Direct Sodium Removal With an Ambulatory Peritoneal Dialysis System: Sequana

Presenter: Jeffrey Testani

September 28, 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

September 16, 2019

Community-Level Salt-Swapping Strategy Pays Dividends in Peru

News Conference News ESC 2019

Community-Level Salt-Swapping Strategy Pays Dividends in Peru

September 09, 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

August 20, 2019

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

News Daily News

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

August 15, 2019

Stricter Regulations Needed to Maximize Cuts in Sodium Intake, UK Study Suggests

News Daily News

Stricter Regulations Needed to Maximize Cuts in Sodium Intake, UK Study Suggests

Marcus A. Banks

July 22, 2019

News Industry News

Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation

June 24, 2019

Device-Based Therapy Offers REPRIEVE From Decongestion in Acute HF

News Conference News ESC Heart Failure 2019

Device-Based Therapy Offers REPRIEVE From Decongestion in Acute HF: TARGET 1 and 2

May 25, 2019

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

News Daily News

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

Yael L. Maxwell

May 16, 2019

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.